- Home
- MVBF vs VCRE Comparison
MVBF vs VCRE Comparison
Compare MVBF & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | MVBF | VCRE |
|---|---|---|
| Founded | 1997 | N/A |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 371.6M | 332.9M |
| IPO Year | 2004 | 2026 |
Fundamental Metrics
Financial Performance| Metric | MVBF | VCRE |
|---|---|---|
| Price | $30.62 | $11.07 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $29.50 | N/A |
| AVG Volume (30 Days) | ★ 47.3K | 7.7K |
| Earning Date | 04-29-2026 | N/A |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | ★ 34.64 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $3,400,000.00 | N/A |
| Revenue This Year | $1.70 | N/A |
| Revenue Next Year | $13.59 | N/A |
| P/E Ratio | $22.92 | ★ N/A |
| Revenue Growth | ★ 51.92 | N/A |
| 52 Week Low | $23.72 | $10.50 |
| 52 Week High | $31.99 | $13.15 |
Technical Indicators
Market Signals| Indicator | MVBF | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 51.75 | 40.71 |
| Support Level | $27.21 | $10.83 |
| Resistance Level | $30.22 | $13.00 |
| Average True Range (ATR) | 0.73 | 0.73 |
| MACD | -0.08 | -0.09 |
| Stochastic Oscillator | 53.63 | 20.00 |
Price Performance
Historical ComparisonAbout MVBF MVB Financial Corp.
MVB Financial Corp is a financial holding company. The company provides a wide range of business activities through the Bank, commercial and retail banking services, as well as Fintech banking. It has three reportable segments: CoRe Banking, Mortgage Banking, and Financial Holding Company. The majority of its revenue is generated from the CoRe Banking segment, which includes its Fintech division, represents banking products and services offered to customers by the Bank, loans and deposits accounts. Revenue from banking activities consists of interest earned on loans and investment securities and service charges on deposit accounts.
About VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.